Anavex Life Sciences is dedicated to advancing brain health by developing innovative oral medicines designed to improve patients lives.
The Journal of Prevention of Alzheimer’s Disease (JPAD) has published peer-reviewed detailed results from the Phase IIb/III study evaluating oral blarcamesine (ANAVEX®2-73) for the treatment of early Alzheimer’s Disease (AD).
ANAVEX®2-73 (blarcamesine) is an investigational oral therapy being studied for its ability to support cellular health by activating SIGMAR1, a receptor that helps restore balance within cells. Researchers are exploring its potential to slow neurodegeneration by boosting autophagy, a natural process that clears protein build-up and misfolded proteins in the brain.
Currently under investigation in Phase IIb/III clinical trials to evaluate its safety and efficacy in early-stage Alzheimer’s.
Research includes a proof-of-concept study examining its potential benefits in Parkinson’s disease dementia.
Autophagy is the body’s natural process of clearing damaged proteins and cellular debris. In Alzheimer’s disease, this process can become impaired, leading to toxic protein buildup. Investigational therapies like blarcamesine aim to restore autophagy, targeting a key mechanism that occurs upstream of amyloid beta and tau.
Blarcamesine (ANAVEX®2-73) is an investigational oral therapy currently being studied for its potential to address conditions such as Alzheimer’s disease, Parkinson’s disease, and Rett syndrome. Research focuses on its ability to enhance autophagy through SIGMAR1 activation, a receptor that plays a key role in cellular processes related to neuroprotection and maintaining homeostasis.
Alzheimer’s Disease (AD) is a progressive and irreversible brain disorder that slowly erodes memory, cognitive abilities, and essential functions for independent living. It is the most common form of dementia and poses significant emotional, physical, and financial challenges for individuals and their families.
Parkinson’s Disease (PD) is a progressive neurological disorder that affects movement, balance, and coordination. It is primarily caused by the degeneration of dopamine-producing neurons in the brain, leading to motor symptoms such as tremors, stiffness, and slowed movement.
Rett Syndrome (RS) is a rare neurological disorder that primarily affects girls, causing severe cognitive, motor, and communication impairments. It is typically diagnosed in early childhood and is often marked by a loss of previously acquired skills.
Blarcamesine (ANAVEX®2-73) is an investigational drug. It is currently undergoing clinical trials and has not been approved by regulatory authorities. This information is intended for educational purposes only and does not suggest safety or efficacy conclusions.
Therapeutic Candidates
We are committed to advancing research into the underlying mechanisms of neurodegenerative and neurodevelopmental diseases. Our investigational therapies are designed to address these challenges through innovative approaches currently being evaluated in clinical trials.
An investigational therapy being studied for Alzheimer’s, Parkinson’s, and Rett syndrome.
Currently in preclinical evaluation for neurodegenerative conditions.
A preclinical-stage compound for central nervous system disorders.
View Anavex’s upcoming participation in scientific, medical, and investor events, including conferences, presentations, and public webcasts.
Explore company announcements covering major milestones, clinical trial results, regulatory developments, and strategic initiatives across our programs.
